Molecular Cancer: Fudan University's team of Chen Tong, Zhang Si's team, Wang Biyun's team of Affiliated Cancer Hospital, and Fu Chaowei's team of School of Public Health provide high-sensitivity, non-invasive tumor chemotherapy liquid biopsy markers

 

Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult point in clinical treatment . Platinum-based chemotherapy is an effective drug for the treatment of triple-negative breast cancer. Researcher Chen Tong and Prof. Zhang Si from Fudan University, together with Prof. Wang Biyun from Affiliated Cancer Hospital and Prof. Fu Chaowei from School of Public Health collaborated to discover a highly accurate, non-invasive tumor chemotherapy liquid biopsy marker: plasma small nucleolar RNA SNORD33 for triple-negative breast cancer Prediction of platinum-based drug sensitivity in cancer patients, and revealed the involvement of methylation-binding protein MeCP2 in the molecular mechanism of platinum-based drug resistance regulated by SNORD33 . The related research results "A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients" were recently published online in the journal Molecular Cancer (IF=27)  SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes. They are abundant in plasma and can be used as potential biomarkers for liquid biopsy . The research team found that the expression of SNORD33 was significantly reduced in cisplatin-resistant triple-negative breast cancer, and down-regulation of SNORD33 promoted cisplatin resistance Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level and possibility of clinical remission at different time of platinum-based drug treatment Further mechanism studies showed that SNORD33 could block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum . (Figure 2)

 Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult point in clinical treatment
.

Platinum-based chemotherapy is an effective drug for the treatment of triple-negative breast cancer.

Researcher Chen Tong and Prof.
Zhang Si from Fudan University, together with Prof.
Wang Biyun from Affiliated Cancer Hospital and Prof.
Fu Chaowei from School of Public Health collaborated to discover a highly accurate, non-invasive tumor chemotherapy liquid biopsy marker: plasma small nucleolar RNA SNORD33 for triple-negative breast cancer Prediction of platinum-based drug sensitivity in cancer patients, and revealed the involvement of methylation-binding protein MeCP2 in the molecular mechanism of platinum-based drug resistance regulated by SNORD33
.

The related research results "A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients" were recently published online in the journal Molecular Cancer (IF=27)

 SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes.
They are abundant in plasma and can be used as potential biomarkers for liquid biopsy
.

The research team found that the expression of SNORD33 was significantly reduced in cisplatin-resistant triple-negative breast cancer, and down-regulation of SNORD33 promoted cisplatin resistance

Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level and possibility of clinical remission at different time of platinum-based drug treatment

    Further mechanism studies showed that SNORD33 could block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum
.

(Figure 2)

 Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult point in clinical treatment
.
Platinum-based chemotherapy is an effective drug for the treatment of triple-negative breast cancer.
However, platinum-based chemotherapy has high economic cost, severe side effects, and patients have different curative effects.
Some patients are insensitive to platinum-based chemotherapy, which delays the treatment window
.
The predictive power of markers, including BRCA mutations, for platinum-based efficacy has been inconsistent across studies
.
Using liquid biopsy markers to predict the therapeutic effect of platinum drugs in advance can avoid ineffective treatment and select an effective treatment plan, which has great socioeconomic significance and clinical application value
.

Researcher Chen Tong and Prof.
Zhang Si from Fudan University, together with Prof.
Wang Biyun from Affiliated Cancer Hospital and Prof.
Fu Chaowei from School of Public Health collaborated to discover a highly accurate, non-invasive tumor chemotherapy liquid biopsy marker: plasma small nucleolar RNA SNORD33 for triple-negative breast cancer Prediction of platinum-based drug sensitivity in cancer patients, and revealed the involvement of methylation-binding protein MeCP2 in the molecular mechanism of platinum-based drug resistance regulated by SNORD33
.
The related research results "A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients" were recently published online in the journal Molecular Cancer (IF=27)
.

 SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes.
They are abundant in plasma and can be used as potential biomarkers for liquid biopsy
.
The research team found that the expression of SNORD33 was significantly reduced in cisplatin-resistant triple-negative breast cancer, and down-regulation of SNORD33 promoted cisplatin resistance
.
Furthermore, in the plasma samples of patients with metastatic triple-negative breast cancer who received platinum-containing and non-platinum regimens in the past, it was found that patients with low plasma SNORD33 levels had significantly shorter progression-free survival (PFS) and overall survival (OS).
Plasma SNORD33 specifically predicted platinum efficacy and was an independent predictor of PFS in patients treated with platinum-containing regimens
.
Based on the status of liver metastases, the clinical characteristics of the number of metastases, and the level of plasma SNORD33, a line array chart was drawn to predict the PFS time of the platinum-containing regimen, which was used to predict the possibility of clinical remission in patients treated with platinum drugs at different times, for clinicians// Refer to the patient to choose a treatment plan
.
(Picture 1)

Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level and possibility of clinical remission at different time of platinum-based drug treatment

    Further mechanism studies showed that SNORD33 could block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum
.
(Figure 2)
.

 Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult point in clinical treatment
.
Platinum-based chemotherapy is an effective drug for the treatment of triple-negative breast cancer.
However, platinum-based chemotherapy has high economic cost, severe side effects, and patients have different curative effects.
Some patients are insensitive to platinum-based chemotherapy, which delays the treatment window
.
The predictive power of markers, including BRCA mutations, for platinum-based efficacy has been inconsistent across studies
.
Using liquid biopsy markers to predict the therapeutic effect of platinum drugs in advance can avoid ineffective treatment and select an effective treatment plan, which has great socioeconomic significance and clinical application value
.

Researcher Chen Tong and Prof.
Zhang Si from Fudan University, together with Prof.
Wang Biyun from Affiliated Cancer Hospital and Prof.
Fu Chaowei from School of Public Health collaborated to discover a highly accurate, non-invasive tumor chemotherapy liquid biopsy marker: plasma small nucleolar RNA SNORD33 for triple-negative breast cancer Prediction of platinum-based drug sensitivity in cancer patients, and revealed the involvement of methylation-binding protein MeCP2 in the molecular mechanism of platinum-based drug resistance regulated by SNORD33
.
The related research results "A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients" were recently published online in the journal Molecular Cancer (IF=27)
.

 SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes.
They are abundant in plasma and can be used as potential biomarkers for liquid biopsy
.
The research team found that the expression of SNORD33 was significantly reduced in cisplatin-resistant triple-negative breast cancer, and down-regulation of SNORD33 promoted cisplatin resistance
.
Furthermore, in the plasma samples of patients with metastatic triple-negative breast cancer who received platinum-containing and non-platinum regimens in the past, it was found that patients with low plasma SNORD33 levels had significantly shorter progression-free survival (PFS) and overall survival (OS).
Plasma SNORD33 specifically predicted platinum efficacy and was an independent predictor of PFS in patients treated with platinum-containing regimens
.
Based on the status of liver metastases, the clinical characteristics of the number of metastases, and the level of plasma SNORD33, a line array chart was drawn to predict the PFS time of the platinum-containing regimen, which was used to predict the possibility of clinical remission in patients treated with platinum drugs at different times, for clinicians// Refer to the patient to choose a treatment plan
.
(Picture 1)

Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level and possibility of clinical remission at different time of platinum-based drug treatment

    Further mechanism studies showed that SNORD33 could block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum
.
(Figure 2)
.

 Triple-negative breast cancer is a subtype of breast cancer with high invasiveness and metastasis, high recurrence rate and low overall survival rate, which is a difficult point in clinical treatment
.
Platinum-based chemotherapy is an effective drug for the treatment of triple-negative breast cancer.
However, platinum-based chemotherapy has high economic cost, severe side effects, and patients have different curative effects.
Some patients are insensitive to platinum-based chemotherapy, which delays the treatment window
.
The predictive power of markers, including BRCA mutations, for platinum-based efficacy has been inconsistent across studies
.
Using liquid biopsy markers to predict the therapeutic effect of platinum drugs in advance can avoid ineffective treatment and select an effective treatment plan, which has great socioeconomic significance and clinical application value
.

breast cancer

Researcher Chen Tong and Prof.
Zhang Si from Fudan University, together with Prof.
Wang Biyun from Affiliated Cancer Hospital and Prof.
Fu Chaowei from School of Public Health collaborated to discover a highly accurate, non-invasive tumor chemotherapy liquid biopsy marker: plasma small nucleolar RNA SNORD33 for triple-negative breast cancer Prediction of platinum-based drug sensitivity in cancer patients, and revealed the involvement of methylation-binding protein MeCP2 in the molecular mechanism of platinum-based drug resistance regulated by SNORD33
.
The related research results "A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients" were recently published online in the journal Molecular Cancer (IF=27)
.

 SnoRNAs are a class of small non-coding RNAs that participate in the biosynthesis of ribosomes and the splicing and assembly of spliceosomes.
They are abundant in plasma and can be used as potential biomarkers for liquid biopsy
.
The research team found that the expression of SNORD33 was significantly reduced in cisplatin-resistant triple-negative breast cancer, and down-regulation of SNORD33 promoted cisplatin resistance
.
Furthermore, in the plasma samples of patients with metastatic triple-negative breast cancer who received platinum-containing and non-platinum regimens in the past, it was found that patients with low plasma SNORD33 levels had significantly shorter progression-free survival (PFS) and overall survival (OS).
Plasma SNORD33 specifically predicted platinum efficacy and was an independent predictor of PFS in patients treated with platinum-containing regimens
.
Based on the status of liver metastases, the clinical characteristics of the number of metastases, and the level of plasma SNORD33, a line array chart was drawn to predict the PFS time of the platinum-containing regimen, which was used to predict the possibility of clinical remission in patients treated with platinum drugs at different times, for clinicians// Refer to the patient to choose a treatment plan
.
(Picture 1)

Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level and possibility of clinical remission at different time of platinum-based drug treatment

Figure 1: Figure 1: Nomogram for predicting PFS time of platinum-containing regimen, SNORD33 level of platinum-based drug treatment for different time periods of clinical remission probability predicting PFS time of platinum-based regimen Likelihood of clinical remission

    Further mechanism studies showed that SNORD33 could block the binding of the methylation-binding protein MeCP2 to its target genes, thereby releasing the transcriptional inhibitory activity of MeCP2, promoting the expression of apoptosis-related genes, and increasing the sensitivity of triple-negative breast cancer cells to platinum
.
(Figure 2)
.

Figure 2: SNORD33 interacts with the methylation-binding protein MeCP2, hindering its binding to target genes, thereby promoting the expression of apoptosis-related genes and increasing the sensitivity of triple-negative breast cancer cells to platinum

Figure 2: SNORD33 interacts with the methylation-binding protein MeCP2, hindering its binding to target genes, thereby promoting the expression of apoptosis-related genes and increasing the sensitivity of triple-negative breast cancer cells to platinum .
Figure 2: SNORD33 and methylation The binding protein MeCP2 interacts and blocks its binding to target genes, thereby promoting the expression of apoptosis-related genes and increasing the sensitivity of triple-negative breast cancer cells to platinum

The results of this study provide a novel liquid biopsy marker with high accuracy, convenient detection, and non-invasiveness
.
Collecting 0.
2 ml of plasma to detect the level of SNORD33, combined with clinical characteristics, can predict the efficacy of platinum drugs in metastatic triple-negative breast cancer, bringing more benefits to tumor patients
.
The application of platinum-containing treatment regimens in neoadjuvant chemotherapy and other cancer patients, the relevant verification work is being carried out in an orderly manner
.

The results of this study provide a novel liquid biopsy marker with high accuracy, convenient detection, and non-invasiveness
.
Collecting 0.
2 ml of plasma to detect the level of SNORD33, combined with clinical characteristics, can predict the efficacy of platinum drugs in metastatic triple-negative breast cancer, bringing more benefits to tumor patients
.
The application of platinum-containing treatment regimens in neoadjuvant chemotherapy and other cancer patients, the relevant verification work is being carried out in an orderly manner
.

Professor Wang Biyun, Physician Zhao Yannan, Physician Li Yi, Associate Professor Xu Yingying of Fudan University are the co-first authors, Researcher Chen Yu, Fudan University Professor Zhang Si, Professor Fu Zhaowei of School of Public Health, and Professor Hu Xichun of Affiliated Cancer Hospital Co-corresponding author
.
This research was supported by the National Natural Science Foundation
of China .
This research was funded by the National Natural Science Foundation of China
.

Professor Wang Biyun, Physician Zhao Yannan, Physician Li Yi, Associate Professor Xu Yingying of Fudan University are the co-first authors, Researcher Chen Yu, Fudan University Professor Zhang Si, Professor Fu Zhaowei of School of Public Health, and Professor Hu Xichun of Affiliated Cancer Hospital Co-corresponding author
.
This research was supported by the National Natural Science Foundation of China
.
This research was funded by the National Natural Science Foundation of China
.

 

  

Article information and links:

Article information and links: Article information and links:

Biyun Wang1#, Yannan Zhao1,2#, Yi Li1,2#, Yingying Xu2#, Yun Chen3, Qiuyu Jiang2,4, Dingjin Yao2, Li Zhang2, Xichun Hu1*, Chaowei Fu3*, Si Zhang2*, She Chen2*.
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.

Biyun Wang1#, Yannan Zhao1,2#, Yi Li1,2#, Yingying Xu2#, Yun Chen3, Qiuyu Jiang2,4, Dingjin Yao2, Li Zhang2, Xichun Hu1*, Chaowei Fu3*, Si Zhang2*, She Chen2*.
A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients.

 https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-022-01504-0

 https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-022-01504-0 Leave a message here